Related Experiment Video
Updated: May 19, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Validity of reported Medicare Part D enrollment in the Medical Expenditure Panel Survey
Steven C Hill1, Samuel H Zuvekas, Marc W Zodet
1Center for Financing, Access and Cost Trends, Agency for Healthcare Research and Quality, 540 Gaither Rd, Rockville, MD 20850, USA. steven.hill@ahrq.hhs.gov
Abstract:
The authors validate reported Part D coverage in the Medical Expenditure Panel Survey (MEPS) and assess the impact of misreporting on descriptive and behavioral analyses. MEPS participants with Medicare coverage during 2006 to 2007 were matched to Medicare administrative data. A summary measure of Part D coverage based on several questions has substantial validity (κ = .70) and an agreement rate of 85.1%. Some beneficiaries confused Part D and private drug coverage, leading to both under- and overreported Part D coverage. Accuracy varies little by sociodemographic group. Standard regression models of the determinants of Part D enrollment were estimated with both MEPS-based and administrative data-based measures of Part D enrollment. In this analysis, the signs of the marginal effects were the same, the magnitudes were similar, and mostly the same variables had statistically significant effects in both regressions. Thus, behavioral analyses are largely unaffected by misreporting.
Related Concept Videos
Dosage Regimens: Partial Pharmacokinetic Parameters
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Analysis of Population Pharmacokinetic Data
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Kaplan-Meier Approach
Therapeutic Drug Monitoring: Drug Analysis Methods